Clarkson Law Firm filed a proposed class action lawsuit Thursday against smart ring maker Oura on behalf of Madison Surber, a California woman who says she paid roughly $514 for an Oura Ring 4 in May 2025. The complaint alleges the company misled customers about how accurately its devices track sleep.
The filing claims the ring lacks any sensor capable of detecting the biological signals that define sleep stages. According to the lawsuit, Oura instead processes the wearer's heart rate, movement, and skin temperature through a machine-learning model that produces an estimate described in the complaint as having "a coin flip's chance of being correct."
Oura disputed the allegations. The company told USA Today it rejects the claims and intends to defend against them. The company did not immediately respond to requests for additional comment.
What the Left Is Saying
Consumer advocates and progressive groups say the lawsuit highlights broader concerns about health technology companies making accuracy claims without sufficient scientific backing. Ryan Clarkson, co-founder and managing partner at Clarkson Law Firm, said in a statement: "When people rely on a device to guide decisions about their health, misinformation cannot be tolerated." He added that Oura users trust numbers displayed by the app reflect physiological reality.
Democratic consumer protection advocates have long argued that wearable health devices operate with insufficient oversight. The lawsuit comes as some Democratic lawmakers have pushed for greater Federal Trade Commission authority over health-related advertising claims made by technology companies.
"People structure their days, interpret the way they feel, and design their lives around inaccurate figures spit out by these devices," Clarkson said in his statement. "Marketing an inaccurate sleep tracker as precise and reliable is dangerous because people believe it — and change their behavior accordingly." Some progressive health policy advocates argue this case could set precedent for how FDA-adjacent claims are regulated when they fall outside traditional medical device oversight.
What the Right Is Saying
Conservative legal observers and business groups say the lawsuit raises concerns about excessive litigation targeting innovative technology companies. Tort reform advocates argue that class action filings over product performance claims can chill investment in consumer health technology.
The company has advertised 79% agreement with polysomnography — the overnight lab study considered the clinical benchmark for sleep staging — when sorting wake, light, deep, and REM stages. Oura's marketing materials have described its rings as "[b]uilt for accuracy" and promised "Unparalleled Accuracy," according to the complaint.
Some Republican lawmakers have expressed skepticism about expanding regulatory authority over consumer wearables, arguing that existing false advertising law provides adequate recourse without additional government mandates. Industry groups contend that setting stricter accuracy standards for consumer sleep trackers could limit product development and increase costs for consumers seeking health insights.
What the Numbers Show
According to the complaint, Oura rings are priced between $300 and more than $500 depending on model and finish. The lawsuit cites screenshots of user complaints from a Facebook owners' group and the Oura subreddit where users describe receiving high sleep scores despite feeling exhausted upon waking.
The filing argues that sleep staging is defined by brain wave activity, eye movement, and muscle tone — signals typically captured through scalp electrodes and leads placed near the eyes and chin. The complaint states these measurements "cannot be taken from one's finger," raising questions about how any finger-worn device can accurately categorize sleep stages.
Oura has advertised 79% agreement with clinical polysomnography for its sleep staging algorithms, a figure that places performance below but approaching clinical standards. More recently, Oura's product pages have promoted "95% Sleep Staging Accuracy compared to clinical sleep lab" for the newer Ring 5 model.
Consumer sleep tracking devices broadly have faced questions about accuracy since their market expansion. Research has shown significant variation in how consumer wearables compare to clinical measurements, with most falling short of hospital-grade polysomnography equipment used in sleep studies.
The Bottom Line
The lawsuit seeks an injunction ordering Oura to stop advertising capabilities the firm argues the rings cannot deliver, along with restitution for customers who purchased products based on allegedly misleading claims. A court has not yet certified the proposed class action.
Oura's defense hinges on whether courts view its marketing language as objective accuracy claims or aspirational descriptions of product intent. The case could influence how health technology companies phrase sleep tracking claims in future advertising.
The Federal Trade Commission has increasingly focused on digital health claims, though this lawsuit is a private action rather than a regulatory proceeding. Watch for Oura's response filing and whether the company moves to compel arbitration — its user agreement may affect which court hears the case.